StreetInsider.com News Articles

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

LAS VEGAS and VANCOUVER, BC, March 9, 2026 /PRNewswire/ - Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a provider of compliant digital health infrastructure and on-demand healthcare services across the United States, announces today its intention to make a normal course issuer bid (the "Bid") to purchase for cancellation, from time to time, as it considers advisable, up to 4,951,189 of its issued and outstanding common shares, being approximately 9.27% of the Company's currently outstanding common shares and approximately

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Announces Normal Course Issuer Bid

Mon, 09 Mar 2026 08:00:00 -0400

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

Wed, 19 Feb 2025 07:30:00 -0400

Vancouver, British Columbia and Las Vegas, Nevada--(Newsfile Corp. - February 19, 2025) - Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a fast-growing mobile clinical network and medical platform, is pleased to announce that it has been included in the 2025 TSX Venture 50™ list. The TSX Venture 50™ recognizes the top-performing companies from over 1,600 issuers listed on the TSX Venture Exchange (TSXV) based on market capitalization growth, share price appreciation, and trading volume over the past year. In 2024, Hydreight Technologies Inc. also was ranked 9th in Canada and 56th in North America

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

Wed, 19 Feb 2025 07:30:00 -0400

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

Wed, 19 Feb 2025 07:30:00 -0400

Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company

Wed, 19 Feb 2025 07:30:00 -0400

Victory Square Technologies Reports 2024 Achievements and Outlines 2025 Strategic Vision

Thu, 30 Jan 2025 03:05:00 -0400

Significant Net Income Growth: Victory Square achieved $10.7M in Q3 net income
Unaudited Net Asset Value (NAV): Estimated at $127,524,464* as of January 28, 2025 (see Use of Non-GAAP Financial Measures).
Digital Health Expansion: The VSDHOne platform powers healthcare brands across all 50 U.S. states, offering telehealth, compliance solutions, and direct-to-consumer scalability.
Hydreight Technologies' Milestones: Hydreight ranked #56 on the 2024 Deloitte Technology Fast 500™, achieved profitability in 2024, and launched a $10M Health Accelerator to foster the next generation of digital health entrepreneurs.
Diabetes Care Advancements: Insu Therapeutics is developing oral delivery technology for insulin and peptide-based drugs, targeting the $118B global diabetes